Recent Updates
Recently added Catalysts

Furosemide for administration

Phase 1

Heart Failure | Small molecule | Cardiovascular |MannKind Corporation|Last Updated: Jun 27, 2018

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedCONTROLLED
Total Trials1
Total Enrollment10

FDA Designations

No designations recorded

Clinical trial landscape

Furosemide for administration · 1 trial · 1 indication

Phase 1 1
NCT02350725Furosemide Pharmacodynamics and Pharmacokinetics After Subcutaneous or Oral AdministrationHeart Failure
COMPLETED10 Analytics
PHASE1COMPLETED
Furosemide Pharmacodynamics and Pharmacokinetics After Subcutaneous or Oral Administration
Heart FailureUnlock trial analytics

Study Endpoints

Primary Endpoints

Diuresis and natriuresis
8 hours

Statistical summaries with a graphical presentation will show mean and individual diuresis and natriuresis time profiles such as time to first void, volume of first void, diuresis and natriuresis measured at 60 minute intervals up to 480 minutes following furosemide injection solution for subcutaneous administration or oral tablets. The diuretic response will be compared between therapies using t-tests or Wilcoxon test.

Secondary Endpoints

Body Water Content
8 hours
Pharmacokinetic profiles
8 hours
Cardiac Markers (NTpro-BNP, hs-Trop T, galectin-3)
8 hours
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Group 1EXPERIMENTALFurosemide injection solution for subcutaneous administration (80 mg) over 5 hours followed by Oral Furosemide tablets (80 mg) in second period.
Group 2EXPERIMENTALOral Furosemide tablets (80 mg) followed by Furosemide injection solution for subcutaneous administration (80 mg) over 5 hours in second period.

Interventions

NameTypeDescription
Furosemide injection solution for subcutaneous administration (80 mg)DRUG -
Oral Furosemide tablets (80 mg)DRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Written informed consent obtained before any assessment is performed * Male and female subjects ≥18 years of age, with body weight \<120 kg and body mass index (BMI) \<30 kg/m2 * Female subjects must be at least 2 years post-menopausal * Participant must have been on oral furo...

Countries:Netherlands
Unlock Eligibility Criteria